Press Releases

Report Date Files
Portage's Biohaven Completes Single Dose Phase of Pharmacokinetic Trial with BHV-0223 21 September 2015 Click to open
Portage's PPL Will Advance its Lead Candidate PPL-003 to an IND for Dry Eye Disease and Uveitis 31 August 2015 Click to open
Portage's Biohaven Doses First Human Subject in Phase I Trial with Lead Drug Candidate BHV-0223 27 August 2015 Click to open
Portage's Biohaven Acquires Intellectual Property for Portfolio of Prodrugs from ALS Biopharma, LLC 18 August 2015 Click to open
Portage's Biohaven Raises US$4.1 Million in First Tranche of Private Placement. Portage Invests $2.5M 11 August 2015 Click to open
Portage Invests in Sentien Biotechnologies, Inc. 10 August 2015 Click to open
Portage's Biohaven Announces IND Filing for BHV-0223 for Phase I Clinical Testing 23 July 2015 Click to open
Portage Completes Non-Brokered Private Placement in Two Tranches for Total Proceeds of US$ 5,155,080 25 June 2015 Click to open
Portage Closes First Tranche of Private Placement 16 June 2015 Click to open
Portage's Biohaven to Begin Phase I Study in 3Q 2015 and Readying for Phase III Study Start by Q1 2016 22 April 2015 Click to open
Portage's CPP Platform Delivers a Peptide Cargo Across the Blood Brain BArrier 20 April 2015 Click to open
Portage to Present at Master Investor 2015 UK 15 April 2015 Click to open
Portage's Biohaven Announces Agreement with Inventiv Health 01 April 2015 Click to open
Portage's Biohaven Enters into Exclusive Formulation Agreement and Global License with Catalent for Lead Product 24 March 2015 Click to open
Portage's Biohaven Receives Response from FDA to its Pre-IND Meeting Request 18 December 2014 Click to open